...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
AGORACOM NEWS FLASH

BREAKING: Esports Entertainment Group Releases Upgraded VIE.GG Esports Gambling Platform

  • Announced the release of the latest version of VIE.gg (https://vie.gg)  the Company’s esports wagering platform
  • Latest upgrade delivers notable new features, including additional betting options such as Fixed Odds, Pari-mutuel, Fantasy and Pool Betting to complement main P2P option
  • Grant Johnson, CEO of Esports Entertainment Group, stated "This is another major milestone for our Company. This is our strongest release ever, with every new feature esports gambling enthusiasts could wish for in a platform..."
Message: Trial

That was my point.Bear posted that the results of the trial should be coming soon.The fact that 44of 58 patients in the trial are Invited to remain on the combo would seem to indicate a degree of success or am I dreaming in technicolour 

Share
New Message
Please login to post a reply